Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US patients receiving free samples spend more on drugs
According to the study, patients who never received drug samples had $178 estimated out-of-pocket prescription costs over six months, while those receiving samples spent an estimated $166 for
According to the study, patients who never received drug samples had $178 estimated out-of-pocket prescription costs over six months, while those receiving samples spent an estimated $166 for
According to the survey, 92% of respondents rated global cost reduction as a key issue, while 56% felt it was the role of CFOs to lead cost reduction
According to the data from Insight Health, for 92% of the 84,000 pharmaceutical products available, prices will be the same as last month, while 4.4% of them will
As part of the appeal process, Labopharm has requested a meeting with Janet Woodcock, the FDA’s director, Center for Drug Evaluation and Research. The Agency usually grants such
Advanced Medical Optics (AMO) claims that its advanced formula for blink Tears lubricating eye drops includes a blend of ingredients naturally found in the eye. The product is
These findings suggest the value of Haptoglobin testing in people with diabetes in order to ensure more successful treatment in the prevention of cardiovascular events (such as heart
Protectan CBLB502 was administered as a single injection at 48 hours post-exposure to 6.5 Gy doses of ionizing radiation, which results in approximately 75% mortality, if untreated (similar
The investment is an extension of the previously announced C round and will allow CoAxia to continue its Sentis pivotal FDA trial of NeuroFlo Perfusion Augmentation Therapy in
Mr Cuevas said: “Hal comes to Interventional Spine with a broad financial background that includes more than 20 years of public accounting experience with Coopers & Lybrand (now
Morgan Stanley & Co. will be the sole underwriter for the offering. The underwriter may offer the shares from time to time in one or more transactions in